|keynote 028 cervical cancer||1.87||1||1805||5|
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without bevacizumab. Download a PDF of the Research Summary.What is the best treatment for cervical cancer?
Cervical cancer is one of the most common gynecological tumors, and the majority of early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy (CCRT).What is the keynote-028 trial?
Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. …Is the incidence of cervical cancer increasing or decreasing?
Although the incidence of cervical cancer has been greatly reduced by the use of HPV vaccines and cervical cancer screening (Goodman, 2015), cervical cancer is second in terms of morbidity among gynecological tumors in developing countries (Sahasrabuddhe et al., 2012).